Session 5: What Will Biosimilars Look Like in Five Years?

Back to Agenda

Session 5: What Will Biosimilars Look Like in Five Years?

Session Chair(s)

Anna Welch, MA

Chief Editor, Biosimilar Development

Life Science Connect, United States

As biosimilar stakeholders evaluate the appropriate metrics of success for the current wave of products, it’s important to consider how the industry’s market dynamics may shift in the future. Looking ahead, there are several critical questions to consider, including:

Which company models will be best suited for the future market, and why?
What types of products will be chosen as future biosimilar development candidates?
What development challenges will these products pose for companies?
How will companies strive to differentiate their biosimilar products or development process?

This session will visualize what the future biosimilar industry may look like. In doing so, stakeholders will better understand the challenges that must be addressed today to arrive at a sustainable and productive future.

Learning Objective : At the conclusion of this session, participants should be able to:
Evaluate the next wave of the biosimilar pipeline and the opportunities/challenges it will pose for the industry
Understand best business practices (i.e., product selection and differentiation strategies) that can be employed to remain in the biosimilar market long-term
Evaluate novel manufacturing and outsourcing strategies to reduce COGs

Speaker(s)

Speaker

Murray Aitken, MBA

IQVIA Institute for Human Data Science, United States

Executive Director

Speaker

Michiel Ultee, PhD, MS

Ulteemit Bioconsulting, United States

Principal

Speaker

Alexandra Moulson, MBA, MS

Polpharma Biologics, Poland

VP Strategy, Programs and Portfolio

Speaker

George I'ons

Owen Mumford, Ltd, United Kingdom

Head of Product Strategy & Insights

Have an account?

Biosimilars Conference